Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Semaglutide (aka Ozempic or Wegovy) has become ubiquitous because of established benefits in diabetes and obesity but SELECT showed that the drug should be considered in those who are obese with established atherosclerotic CV disease (ASCVD.) In March of 2024 the FDA approved a new indication for Wegovy based on the SELECT trial to reduce the risk of CV death, stroke, and heart attack in adults with cardiovascular disease and either obese or overweight My Thoughts on Semaglutide for Secondary Prevention After looking in detail at SELECT I realized that it does not apply to most patients in my practice
The American Diabetes Association recommends A1C testing every 3 months when therapy changes or targets are not met
HbA1c trending upward
Proper hydration is essential for maintaining energy levels and overall well-being
